ACADIA Pharmaceuticals Inc.
ACAD
Classificação em ações
#4508
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Preço da ação
$19.76
Última sincronização: 2026-10-19
Valor de mercado
$3.40B
Variação (1 dia)
3.32%
Variação (1 ano)
-5.66%
País
US
Negociar ACADIA Pharmaceuticals Inc. (ACAD)
Categoria
Healthcare
EPS de ACADIA Pharmaceuticals Inc. (ACAD)
EPS em June 2026 TTM: $2.25
De acordo com os últimos relatórios financeiros e o preço das ações da ACADIA Pharmaceuticals Inc., o EPS atual da empresa (TTM) é $2.25. No final de 2023, a empresa teve um EPS de $-0.37, uma diminuição em relação a ao EPS de 2022, que foi de $-1.34.
Histórico de EPS da ACADIA Pharmaceuticals Inc. de 2000 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $2.25 | 64.23% |
| 2024 | $1.37 | -470.27% |
| 2023 | $-0.37 | -72.39% |
| 2022 | $-1.34 | 27.62% |
| 2021 | $-1.05 | -41.34% |
| 2020 | $-1.79 | 11.88% |
| 2019 | $-1.60 | -17.53% |
| 2018 | $-1.94 | -17.80% |
| 2017 | $-2.36 | 0.85% |
| 2016 | $-2.34 | 43.56% |
| 2015 | $-1.63 | 71.58% |
| 2014 | $-0.95 | 115.91% |
| 2013 | $-0.44 | 15.79% |
| 2012 | $-0.38 | -13.64% |
| 2011 | $-0.44 | -212.82% |
| 2010 | $0.39 | -132.50% |
| 2009 | $-1.20 | -30.64% |
| 2008 | $-1.73 | 8.12% |
| 2007 | $-1.60 | -0.62% |
| 2006 | $-1.61 | 3.87% |
| 2005 | $-1.55 | -38.00% |
| 2004 | $-2.50 | -74.12% |
| 2003 | $-9.66 | 9.03% |
| 2002 | $-8.86 | -25.73% |
| 2001 | $-11.93 | 25.18% |
| 2000 | $-9.53 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | 669.78% |
US
|
|
| $-7.98 | -454.67% |
US
|
|
| $-5.29 | -335.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,132.89% |
NL
|
